RTX Fintech & Research (“RTX Fintech”), a leading US electronic interdealer trading platform for interest rate swaps, today announced the appointment of André Léger as Chief Product Officer and Head of Markets, Asia. Léger will be responsible for driving RTX's end-to-end product development and global platform roadmap, while enhancing platform functionality through integrated market research […]

IAB NewFronts Moves to March to Align with Buyer Demand Fall 2026 Lineup Combines IAB PlayFronts, IAB Podcast Upfront, and Launches First-EverIAB CreatorFronts Across a Single Week Today the Interactive Advertising Bureau (IAB), the leading trade body for the digital advertising industry, unveiled strategic changes to its 2026 calendar of marketplace events, reinforcing its commitment

In this free webinar, gain insights about the differences between GMP and USP compounding in research. Attendees will learn that although USP can support certain research needs, it falls short when robust data integrity, reproducibility and regulatory compliance are required, particularly in early phase clinical trials. The featured speakers will share real-world case studies, where

FT. LAUDERDALE, FL, 2654 / ACCESS Newswire / October 21, 2025 / Kaya Holdings, Inc. (OTCQB:KAYS) (the "Company" or "KAYS") confirmed that its newly formed cryptocurrency operating subsidiary is conducting ongoing discussions with cryptocurrency foundations and other entities/individuals through its representatives Thomas Gaffney of Conduit Advisors ("Thomas") and the team at Greentree Financial Group ("Greentree")

In this free webinar, learn how expert-led pathology supports translational research and clinical trials at every stage. Attendees will gain insight into how expert pathology leadership supports trial design and execution. The featured speaker will discuss the role of digital pathology in enabling faster turnarounds and global collaboration. Attendees will also understand why pathology should

Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout GlobeNewswire October 21, 2025 MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) — Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics,

Today marks the official launch of Oakledge Advisors, a new independent advisory firm founded to help institutional investors, asset managers, and ecosystem partners navigate the challenges and opportunities of aligning long-term capital with the evolving economy and disrupted climate system. Drawing on more than 15 years of experience in sustainable finance and policy – including

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced it will release its third quarter 2025 financial and operating results on Monday, November 3, 2025, following the close of trading. Halozyme will host a conference call on Monday, November 3, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be

Prospectively designed for scalability and re-dosability, Immusoft's engineered B cells represent the next generation of advanced therapeutics Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ISP-001, the Company's lead investigational therapy for the treatment of

Quad/Graphics, Inc. (NYSE: QUAD) (“Quad” or the “Company”), a marketing experience company that solves complex marketing challenges for its clients, today announced that its Board of Directors declared a quarterly dividend on the Company's common stock of $0.075 per share. https://mma.prnewswire.com/media/2429040/Quad_Wordmark_Logo.jpg The dividend is payable on December 5, 2025, to shareholders of record as of